-
Period: to
The rise and fall of DMAA
-
DMAA concerns begin to ‘bubble over’ into public domain
As reported by NutraIngredients-USA, early concerns about the ingredient began to 'bubble over' into the public domain in early 2011.
Anthony Almada, a biochemist and president and CEO of GENr8, told us that he expected a "mushroom cloud sighting before summer". -
Health Canada says DMAA is a drug
Health Canada takes the bold step of ruling that DMAA is not isolated from plants and products containing it need drug authorization.
The Agency analyzed the controversial Ping paper from 1996, and noted that the Chinese paper contains ‘errors’, and added that at least seven other papers have failed to identify DMAA in geranium oil. -
AHPA introduces DMAA labeling requirement
The American Herbal Products Association introduced a trade requirement for its members to not label DMAA as geranium oil or as any part of the geranium plant, whether by the common name of geranium or by the botanical name of any plant known as geranium (Pelargonium spp.). -
US Army removes DMAA products from military facility shelves
The US Army announced a temporary ban on sales of products containing DMAA within military facilities following links to two recent soldier deaths. -
USP Labs hit with class action
Texas-based USPLabs is hit with a class action in California, with the Plaintiff claiming that the supplements OxyELITE Pro and Jack3d contain DMAA in a “synthetic form that is both illegal and dangerous”. -
Class actions continue
GNC, Cellucor Sports Nutrition and others are the next to be targeted in class actions. They are accused of allegedly misleading consumers over the source, regulatory status and safety of DMAA in a class action lawsuit filed in California. -
UK's Medicines and Healthcare products Regulatory Agency (MHRA) wades in
The UK's MHRA began taking action in February by telling companies that they must stop selling DMAA-containing products. -
USPLabs sponsored study says DMAA is safe
Data published in the Journal of Nutrition and Metabolic Insights found that the DMAA-containing, pre-workout sports supplement, Jack3D, does not change resting heart rate, blood pressure or affect liver and kidney function when used at recommended dosage levels.
The study was sponsored by USPLabs. -
New Zealand classes DMAA as 'recreational drug'
New Zealand adds its voice to the debate by classing the compound as a recreational drug.
The New Zealand decision was primarily motivated by recreational misuse of DMAA, with adverse events including a brain haemorrhage being reported in recent years. -
FDA challenges marketing of DMAA products for lack of safety evidence
After much anticipation, the FDA has taken a stance on the ingredient, sending warning letters to ten manufacturers and distributors of dietary supplements containing DMAA.
“Before marketing products containing DMAA, manufacturers and distributors have a responsibility under the law to provide evidence of the safety of their products. They haven’t done that and that makes the products adulterated,” said FDA's Daniel Fabricant, PhD.
